We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cancer Testing Market to Experience Better Than Average Growth

By LabMedica International staff writers
Posted on 12 Mar 2012
In 2011, the personalized medicine testing market exceeded USD 28 billion. More...


The personalized medicine testing market is comprised of tests that are used to determine the appropriate therapeutic on an individual patient. This also includes new molecular tests based on proven biomarkers, as well as routine glucose and microbial identification tests.

According to a report by Kalorama Information (New York, NY, USA) a medical research publisher, tissue diagnostics, in particular tests that determine therapy for cancer, are leading personalized medicine. These should experience better than average IVD industry revenue-growth rates in the next five years.
Pathologists examine specific protein and molecular structures in fixed tissues, body fluids, and cells using personalized tissue-based tests such as the immunohistochemical stain (IHC) and in situ hybridization (ISH). The type of cancer, the stage, and the degree to which the cancer has invaded healthy tissue is determined from biopsies.

“Tissue-based diagnostic testing continues to serve as one of the gold standards for cancer diagnosis,” said Shara Rosen, lead diagnostic analyst for Kalorama Information and author of the report.

To improve patient survival rates, therapies in the oncology marketplace are being combined with predictive biomarkers to help select patients who will respond to specific drugs. The report finds that tissue diagnostics will be in high demand and produce a strong market with many growth opportunities.

The application of pharmacodiagnostic histology is becoming more sophisticated. Many of these tests are used as companion tests for targeted drugs and also in test services. DNA and RNA extracted from tissue samples are analyzed using mass spectroscopy, polymerase chain reaction (PCR), and sequencing. Tests have also been developed to assess radiosensitivity of tumors.

The market leaders in this pharmacodiagnostic histology are Dako (Herzlia, Israel), Abbott Diagnostics (Abbott Park, IL, USA) and Roche/Ventana Medical (Tucson, AZ, USA). China Medical (Beijing, China) is dedicated to making locally produced pharmacodiagnostic histology available.

Kalorama Information supplies the latest independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Kalorama routinely assists the media with healthcare topics.

Related Links:
Kalorama Information
Dako
Roche/Ventana Medical


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Collection and Transport System
PurSafe Plus®
Laboratory Software
ArtelWare
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.